<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000036" GROUP_ID="PREG" ID="388299081020074111" MERGED_FROM="" MODIFIED="2009-08-03 14:35:51 +0200" MODIFIED_BY="Sonja Henderson" NOTES="&lt;p&gt;Short title (no longer in use): Betamimetics for impaired fetal growth&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-08-03 13:34:26 +0100" NOTES_MODIFIED_BY="Sonja L  Henderson" REVIEW_NO="0021" REVMAN_SUB_VERSION="5.0.21" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2009-08-03 14:35:51 +0200" MODIFIED_BY="Sonja Henderson">
<TITLE>Betamimetics for suspected impaired fetal growth</TITLE>
<CONTACT MODIFIED="2009-08-03 14:35:51 +0200" MODIFIED_BY="Sonja Henderson"><PERSON ID="13656" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lale</FIRST_NAME><LAST_NAME>Say</LAST_NAME><POSITION>Scientist, UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP)</POSITION><EMAIL_1>sayl@who.int</EMAIL_1><ADDRESS><DEPARTMENT>Department of Reproductive Health and Research</DEPARTMENT><ORGANISATION>World Health Organization</ORGANISATION><ADDRESS_1>20 Avenue Appia</ADDRESS_1><CITY>Geneva</CITY><ZIP>1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+ 41 22 7914816</PHONE_1><FAX_1>+ 41 22 7914171</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-08-03 14:35:51 +0200" MODIFIED_BY="Sonja Henderson"><PERSON ID="13656" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lale</FIRST_NAME><LAST_NAME>Say</LAST_NAME><POSITION>Scientist, UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP)</POSITION><EMAIL_1>sayl@who.int</EMAIL_1><ADDRESS><DEPARTMENT>Department of Reproductive Health and Research</DEPARTMENT><ORGANISATION>World Health Organization</ORGANISATION><ADDRESS_1>20 Avenue Appia</ADDRESS_1><CITY>Geneva</CITY><ZIP>1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+ 41 22 7914816</PHONE_1><FAX_1>+ 41 22 7914171</FAX_1></ADDRESS></PERSON><PERSON ID="15905" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>A Metin</FIRST_NAME><LAST_NAME>Gülmezoglu</LAST_NAME><POSITION>Scientist</POSITION><EMAIL_1>gulmezoglum@who.int</EMAIL_1><URL>http://www.who.int/reproductive-health/rhl/index.html</URL><ADDRESS><DEPARTMENT>UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Reproductive Health and Research</DEPARTMENT><ORGANISATION>World Health Organization</ORGANISATION><ADDRESS_1>20 Avenue Appia</ADDRESS_1><CITY>Geneva</CITY><ZIP>1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 22 7913417</PHONE_1><FAX_1>+41 22 7914171</FAX_1></ADDRESS></PERSON><PERSON ID="15917" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>G Justus</FIRST_NAME><LAST_NAME>Hofmeyr</LAST_NAME><POSITION>Director/Hon. Professor, Effective Care Research Unit</POSITION><EMAIL_1>gjh@global.co.za</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology, East London Hospital Complex</DEPARTMENT><ORGANISATION>University of the Witwatersrand, University of Fort Hare, Eastern Cape Department of Health</ORGANISATION><ADDRESS_1>Frere and Cecilia Makiwane Hospitals</ADDRESS_1><ADDRESS_2>Private Bag X 9047</ADDRESS_2><CITY>East London</CITY><ZIP>5200</ZIP><REGION>Eastern Cape</REGION><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 43 7092483</PHONE_1><PHONE_2>+27 83 2809402</PHONE_2><FAX_1>+27 43 7092483</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-07-07 10:51:45 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 10/28/07&lt;/p&gt;&lt;p&gt;New studies sought but none found: 10/28/07&lt;/p&gt;&lt;p&gt;Feedback added: 5/1/01&lt;/p&gt;&lt;p&gt;Response to feedback added: 7/23/01&lt;/p&gt;&lt;p&gt;Reformatted: 8/11/99&lt;/p&gt;" NOTES_MODIFIED="2009-07-07 10:51:45 +0100" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="24" MONTH="6" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="24" MONTH="6" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="12" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1995"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1995"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2001"/>
</DATES>
<WHATS_NEW MODIFIED="2009-07-03 16:47:43 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;28 October 2007: search updated but no new trials identified.&lt;br&gt;24 November 2006: search updated but no new trials identified.&lt;br&gt;30 June 2004: search updated but no new trials identified.&lt;/p&gt;" NOTES_MODIFIED="2009-07-03 16:47:43 +0100" NOTES_MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-07-03 16:47:43 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="6" YEAR="2009"/>
<DESCRIPTION>
<P>Search updated. No new trials identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-06-24 12:05:17 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-06-24 12:05:17 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-02-17 17:26:18 +0000" MODIFIED_BY="Sonja Henderson">
<DATE DAY="28" MONTH="10" YEAR="2007"/>
<DESCRIPTION>
<P>Search updated but no new trials identified.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-02-17 17:26:32 +0000" MODIFIED_BY="Sonja Henderson">
<DATE DAY="24" MONTH="11" YEAR="2006"/>
<DESCRIPTION>
<P>Search updated but no new trials identified.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-02-17 17:26:50 +0000" MODIFIED_BY="Sonja Henderson">
<DATE DAY="30" MONTH="6" YEAR="2004"/>
<DESCRIPTION>
<P>Search updated but no new trials identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="31" MONTH="5" YEAR="2001"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of the Witwatersrand</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>UK Cochrane Centre, NHS R&amp;D Programme, Oxford</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>HRP - UNDP/UNFPA/WHO/World Bank Special Programme in Human Reproduction, Geneva</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-08-03 13:34:26 +0100" MODIFIED_BY="Sonja L  Henderson">
<SUMMARY MODIFIED="2009-08-03 13:34:26 +0100" MODIFIED_BY="Sonja L  Henderson">
<TITLE MODIFIED="2008-02-12 09:34:54 +0000" MODIFIED_BY="[Empty name]">Betamimetics for suspected impaired fetal growth</TITLE>
<SUMMARY_BODY MODIFIED="2009-08-03 13:34:26 +0100" MODIFIED_BY="Sonja L  Henderson">
<P>Too little evidence to show whether betamimetic drugs for women during pregnancy benefits unborn babies who are smaller than expected.</P>
<P>Betamimetic drugs such as ritodrine relax muscles and help the body break down sugar found in fruit and meat (glucose) for energy. It has been thought that betamimetic drugs taken by mouth or injection by women who are more than 27 weeks' pregnant may improve the growth of unborn babies who are smaller than expected (impaired fetal growth). The review of two trials (118 women) has found too little evidence to show whether the unborn baby's growth improves when the mother takes betamimetic drugs. More research is needed into the short and long-term effects of betamimetic drugs on women and their babies.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-07-03 16:48:00 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Betamimetic drugs may promote fetal growth by increasing the availability of nutrients and by decreasing vascular resistance. They may also induce adverse effects via their effects on carbohydrate metabolism. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The objective of this review was to assess the effects of betamimetic therapy for suspected impaired fetal growth on fetal growth and perinatal outcome.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-06-24 12:05:58 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (June 2009).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomized trials of betamimetic therapy compared with no betamimetic therapy or placebo in women with suspected impaired fetal growth.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Eligibility and trial quality was assessed.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-07-03 16:48:00 +0100" MODIFIED_BY="[Empty name]">
<P>Two studies of 118 women were included. No statistically significant differences were found between the betamimetic groups and the control groups for low birthweight (risk ratio 1.17, 95% confidence interval 0.75 to 1.83), other anthropometric measures or neonatal morbidity and mortality.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Larger, well-designed studies are needed to evaluate the effects of betamimetics on fetal growth. Since there is potential for adverse effects due to the pharmacological characteristics of this group of drugs, data related to any potential harms should be collected in addition to beneficial effects.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-07-03 16:50:53 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Impaired fetal growth is the failure of a newborn to achieve its genetically determined growth potential, which may cause death as well as short or long-term childhood morbidity. It has been reported that three to 10% of neonates are small for corresponding gestational age and an estimated 30% of this is due to impaired fetal growth. The remaining 70% is due to constitutional factors such as maternal ethnicity, parity, weight and height (<LINK REF="REF-Lin-1998" TYPE="REFERENCE">Lin 1998</LINK>). The condition occurs with limited flow of nutrients or oxygen, or both, from mother to fetus as a result of fetal causes (e.g. chromosomal abnormalities, congenital malformations), placental factors (e.g. small placenta), or maternal factors (e.g. malnutrition, vascular/renal disease, drugs or other metabolic conditions) (<LINK REF="REF-Resnik-2002" TYPE="REFERENCE">Resnik 2002</LINK>). </P>
<P>Ultrasound evaluation of the fetus by measuring the abdominal circumference, head circumference, length of upper leg and interpreting these using standardised formulae allows the clinician to estimate the fetal weight, to relate this to the gestational age and to follow the growth progress. Ultrasound evaluation also allows to some extent to estimate the timing and the cause of the impairment. Symmetrical growth of the fetus is generally due to early problems such as chromosomal abnormalities, drugs, chemical agents or infection. Asymmetric growth usually results from inadequacy of substrates the fetus needs particularly later in pregnancy (<LINK REF="REF-Resnik-2002" TYPE="REFERENCE">Resnik 2002</LINK>). In low-income settings where early pregnancy ultrasound is not available, fetal growth can be monitored by serial symphysis fundus measurements. However, there is no proven effective treatment that can be applied once growth impairment is diagnosed. In general, when no apparent congenital abnormality exists, management is conservative by frequent growth measurements, smoking cessation if the mother smokes and early delivery when the fetus is thought be mature enough to survive outside the womb. </P>
<P>The outcomes of impaired growth are variable and usually related to the specific cause. For example, if the growth impairment is due to chromosomal anomalies or congenital abnormalities, the fetus is more at risk of a perinatal death. Other short-term outcomes may be moderate to mild metabolic problems (hypoglycemia, polycythemia, meconium aspiration, etc.) due to the chronic oxygen and nutrient deprivation. Depending on the severity and the duration of the condition, long-term outcomes may differ from normal to small decreases in IQ to an increased risk of cerebral palsy (<LINK REF="REF-Bernstein-2000" TYPE="REFERENCE">Bernstein 2000</LINK>).</P>
<P>Betamimetic drugs have a range of systemic effects via their action on adrenoreceptors. The main effects that relate to pregnancy and fetal growth seem to be relaxation in the uterine muscular and vascular structures and metabolic effects on glucose metabolism, which are manifest by a rise in blood glucose levels. There is therefore a theoretical basis for promoting fetal growth by increasing the availability of nutrients and by decreasing vascular resistance. There is also the theoretical possibility of inducing adverse effects through effects on the carbohydrate metabolism. Increasing the maternal-fetal glucose gradient by intravenous glucose infusion, for example, has been shown to cause fetal acidaemia (<LINK REF="REF-Harding-1992" TYPE="REFERENCE">Harding 1992</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects on fetal growth and perinatal outcome of betamimetic therapy for suspected impaired fetal growth.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-07-03 16:50:34 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All acceptably randomized controlled trials of betamimetic therapy for suspected impaired fetal growth with or without pre-eclampsia were eligible.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Women with suspected impaired fetal growth.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Betamimetic administration for promoting fetal growth.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Perinatal mortality, neonatal morbidity, neonatal anthropometric measurements, adverse effects on the mother or the neonate.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-06-24 12:06:40 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2009-06-24 12:06:40 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register by contacting the Trials Search Co-ordinator (June 2009). </P>
<P>The Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from: </P>
<OL>
<LI>quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE;</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL and MEDLINE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A>. </P>
<P>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords.  </P>
<P>We did not apply any language restrictions.</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-07-03 16:50:34 +0100" MODIFIED_BY="[Empty name]">
<P>Trials under consideration were evaluated for methodological quality and appropriateness for inclusion according to the prestated selection criteria, without consideration of their results. Individual outcome data were included in the analysis if they met the prestated criteria in '<LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>'. Included trial data were processed as described in <LINK REF="REF-Clarke-2000" TYPE="REFERENCE">Clarke 2000</LINK>.</P>
<P>Data were extracted from the sources and entered onto the Review Manager computer software (<LINK REF="REF-RevMan-2000" TYPE="REFERENCE">RevMan 2000</LINK>), checked for accuracy, and analysed as above using the <LINK REF="REF-RevMan-2000" TYPE="REFERENCE">RevMan 2000</LINK> software. For dichotomous data, risk ratios and 95% confidence intervals were calculated, and in the absence of heterogeneity, results were pooled using a fixed-effect model. Continuous data were pooled using mean differences and 95% confidence intervals.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-07-03 16:50:53 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-07-03 16:50:53 +0100" MODIFIED_BY="[Empty name]">
<P>In total eight studies were considered, six were excluded and two included, which examined 118 women. <I>See</I> '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>The trial of Cabero et al (<LINK REF="STD-Cabero-1988" TYPE="STUDY">Cabero 1988</LINK>) was not blinded nor placebo-controlled. Five participants that should be assigned to the treatment group were assigned to the control group instead of the treatment group due to an error in transcribing the randomized lists. The five women were then considered as part of the control group and analysed with the control group. This erroneous allocation of five participants to the control group, though considered by the authors to be a random error, reduces the methodological soundness of the study. The trial of Mori et al (<LINK REF="STD-Mori-1990" TYPE="STUDY">Mori 1990</LINK>) is available only as an abstract. </P>
<P>The method of randomization and whether outcome assessments were blinded are unclear in both trial reports.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>In the trial of Cabero et al (<LINK REF="STD-Cabero-1988" TYPE="STUDY">Cabero 1988</LINK>) women with ultrasound dating in the third trimester more than two weeks behind menstrual dating were allocated by randomized lists to receive oral ritodrine and hospitalization, or not. Fetal surveillance was more frequent in the group allocated to ritodrine and hospitalization. No significant differences were found between the two groups for any of the outcomes measured but, because of the small numbers studied, clinically important differences may have been missed.</P>
<P>Mori et al (<LINK REF="STD-Mori-1990" TYPE="STUDY">Mori 1990</LINK>) found a significantly greater growth rate of the biparietal diameter in the ritodrine group but there were no statistically significant differences in other ultrasound measurements, Doppler indices or birthweight.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Betamimetic administration to the mother to promote fetal growth has a reasonable theoretical basis. However, the studies to date have been too small to reliably assess any effect on growth outcomes. Since there may be possible hazards in addition to benefits with betamimetic drugs, studies evaluating the effects of these drugs on fetal growth should collect data on possible adverse (clinical and physiological) effects.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>There is a reasonable theoretical basis for investigation of the usefulness of betamimetic therapy for suspected impaired fetal growth, but on the basis of evidence examined in this review, there is no proof of its clinical usefulness. Currently, there is insufficient evidence to support the clinical use of betamimetics to promote fetal growth except in the context of randomized clinical trials.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>The possibility that betamimetic therapy may promote fetal growth either by improving uteroplacental circulation or by increasing blood sugar and plasma insulin levels, needs further investigation. Evidence from physiological studies on its usefulness should also be sought before testing such interventions in large clinical trials. Studies should incorporate strategies to detect possible harmful effects of the impact of the treatment, especially on carbohydrate metabolism.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>None.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Justus Hofmeyr wrote the original review for the Cochrane Pregnancy and Childbirth Database. Metin Gülmezoglu updated the review, and has been responsible for maintaining the review since 1995. Both review authors did the data extraction and contributed to the text of the review. Lale Say contributed to the recent update by checking the data entries and revising the text of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Cabero-1988" NAME="Cabero 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;[4777]&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cabero L, Cerqueira MJ, del Solar J, Bellart J, Esteban-Altirriba J</AU>
<TI>Long-term hospitalization and beta-mimetic therapy in the treatment of intrauterine growth retardation of unknown etiology</TI>
<SO>Journal of Perinatal Medicine</SO>
<YR>1988</YR>
<VL>16</VL>
<PG>453-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mori-1990" NAME="Mori 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;[5909]&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mori H, Aisaka K, Arai K, Okinaga S</AU>
<TI>Trial of ritodrine infusion for treatment of intrauterine growth retardation</TI>
<SO>Proceedings of 6th Congress of the Federation of the Asia-Oceania Perinatal Societies; 1990 Oct 22-26; Perth, Western Australia</SO>
<YR>1990</YR>
<PG>46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Chang-1977" NAME="Chang 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;[1225]&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chang A, Abell D, Beischer N, Wood C</AU>
<TI>Trial of intravenous therapy in women with low urinary oestriol excretion</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1977</YR>
<VL>127</VL>
<PG>793-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Grant-1987" NAME="Grant 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Grant AM</AU>
<TI>Oral salbutamol in the prevention of low birthweight in singleton pregnancies</TI>
<SO>Personal communication</SO>
<YR>January 17 1987</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Renaud-1972" NAME="Renaud 1972" YEAR="1972">
<REFERENCE NOTES="&lt;p&gt;[1107]&lt;br&gt;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brettes JP, Renaud R, Gandar R</AU>
<TI>A double-blind investigation into the effects of ritodrine on uterine blood flow during the third trimester of pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1976</YR>
<VL>124</VL>
<PG>164-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;[775]&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Renaud R, Brettes P, Irrmann M, Boog G, Schumacher J, Gandar R</AU>
<TI>A double-blind cross-over trial to assess the effect of ritodrine on uterine blood flow in normal and pathologic pregnancies. A preliminary report</TI>
<SO>Proceedings of International Symposium on the Treatment of Fetal Risks; 1972 May; Baden, Austria</SO>
<YR>1972</YR>
<PG>53-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Renaud-1976" NAME="Renaud 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;[1187]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Renaud R, Bock A, Chambron J, Bonafous J, Rosenthal C, Raffi F</AU>
<TI>A simultaneous study of the placental, myometrial and cervical circulations (using Indium 113 and anemometric thermometry). A double blind study of the action of intravenous ritodrine in normal pregnancy</TI>
<SO>Journal de Gynecologie, Obstetrique et Biologie de la Reproduction</SO>
<YR>1976</YR>
<VL>5</VL>
<PG>611-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spellacy-1978" NAME="Spellacy 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;[1478]&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spellacy WN, Cruz AC, Buhi WC, Birk SA</AU>
<TI>The acute effects of ritodrine infusion on maternal metabolism: measurement of levels of glucose, insulin, glucagon, triglycerides, cholesterol, placental lactogen and chorionic gonadotropin</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1978</YR>
<VL>131</VL>
<PG>637-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Varma-1987" NAME="Varma 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Varma TR</AU>
<TI>A randomised double-blind comparison of ritodrine vs placebo in the treatment of intrauterine growth retardation</TI>
<SO>Personal communication</SO>
<YR>September 29 1987</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Bernstein-2000" NAME="Bernstein 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bernstein IM, Horbar, JD, Badger GJ, Ohlsson A, Golan A</AU>
<TI>Morbidity and mortality among very low birth weight infants with intrauterine growth restriction. The Vermont Oxford Network</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2000</YR>
<VL>182</VL>
<PG>198</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2000" NAME="Clarke 2000" TYPE="OTHER">
<AU>Clarke M, Oxman AD, editors</AU>
<TI>Cochrane Reviewers' Handbook 4.1 [updated June 2000]</TI>
<SO>In: The Cochrane Library [database on CDROM]. The Cochrane Collaboration. Oxford: Update Software; 2000, Issue 2</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harding-1992" NAME="Harding 1992" TYPE="JOURNAL_ARTICLE">
<AU>Harding JE, Owens JA, Robinson JS</AU>
<TI>Should we try to supplement the growth retarded fetus? A cautionary tale</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1992</YR>
<VL>99</VL>
<PG>707-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lin-1998" NAME="Lin 1998" TYPE="JOURNAL_ARTICLE">
<AU>Lin C, Santolaya-Forgas J</AU>
<TI>Current concepts of fetal growth restriction: Part 1. Causes, classification, and pathophysiology</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1998</YR>
<VL>92</VL>
<NO>6</NO>
<PG>1044-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Resnik-2002" NAME="Resnik 2002" TYPE="JOURNAL_ARTICLE">
<AU>Resnik R</AU>
<TI>Intrauterine growth restriction</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2002</YR>
<VL>99</VL>
<NO>3</NO>
<PG>490-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2000" NAME="RevMan 2000" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2000</YR>
<EN>4.1 for Windows</EN>
<PB>The Cochrane Collaboration</PB>
<CY>Oxford, England</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-07-03 16:52:15 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Cabero-1988">
<CHAR_METHODS>
<P>Women were randomly assigned to 2 groups. No blinding was used.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>98 women (44 in the intervention arm, 54 in the control arm) in third trimester with a difference of more than 2 weeks in gestational age between ultrasound dating (by biparietal diameter, cephalic area, cephalic perimeter and abdominal area and perimeter) and menstrual age.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ritodrine 10 mg 8 hourly orally + bed rest in hospital + high calorie, vitamin and mineral supplemented diet volumetric solution variable hospital stay (no explanation given) + rest at home + high calorie diet with fetal movement counting.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean birthweight, caesarean section, umbilical artery pH and perinatal mortality.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The outcomes in this study are more related to labour and immediate delivery outcomes. The time women stayed in the study (15+/-5 days) is probably not long enough to evaluate any effects, if any, on fetal growth.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mori-1990">
<CHAR_METHODS>
<P>Women were randomly allocated to 2 groups. It is not clear whether there was any blinding in allocation, performance and outcome assessments.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>20 women (10 in the intervention arm and 10 in the control arm) less than 37 weeks' pregnant who had a diagnosis of intrauterine growth retardation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ritodrine infusion versus dextrose as control. No doses given.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Various fetal biometrical measurements and umbilical artery doppler studies.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Only abstract available with very few details. ? no full publication since 1990.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-07-03 16:52:15 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Chang-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>No clinical outcomes. Ritodrine infusion did not differ from Hartmann's solution, aminoacid or 10% dextrose solution with respect to urinary oestriol excretion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Grant-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>No publication of this trial has been located.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-03 16:52:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Renaud-1972">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-03 16:52:15 +0100" MODIFIED_BY="[Empty name]">
<P>This randomized, double-blind, cross-over trial was reported as an abstract in 1972 and fully in 1976. It was not possible to analyse the data from the 2 phases of the trial separately. Therefore, it was considered more appropriate to exclude this trial. 29 women, 18 with healthy pregnancy and 11 women with impaired fetal growth or hypertensive pregnancies were studied. Ritodrine or placebo was infused in gradually increased doses and cervical flow measured by a probe inserted into the cervical canal. Ritodrine infusion was associated with increased cervical blood flow in the group of women with pregnancies complicated by impaired fetal growth or hypertension.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Renaud-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Physiological study in healthy women.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Spellacy-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>No clinical outcomes. Blood glucose and plasma insulin levels were increased during 12 hours of treatment with intravenous ritodrine compared with randomly selected placebo-treated controls. This raises the possibility that any effect of betamimetic therapy on fetal growth may be the result of changes in carbohydrate metabolism rather than placental perfusion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Varma-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>No publication of this trial has been located.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cabero-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mori-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Ritodrine versus control</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8302897993865281" CI_START="0.7498174361017169" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.171487603305785" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.26251985929873645" LOG_CI_START="-0.1250444648017483" LOG_EFFECT_SIZE="0.06873769724849409" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.48691040823006715" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="54" WEIGHT="99.99999999999999" Z="0.6952312305832171">
<NAME>Low birthweight for gestational age</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="1.8302897993865281" CI_START="0.7498174361017169" EFFECT_SIZE="1.171487603305785" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.26251985929873645" LOG_CI_START="-0.1250444648017483" LOG_EFFECT_SIZE="0.06873769724849409" ORDER="1" O_E="0.0" SE="0.22765720245096976" STUDY_ID="STD-Cabero-1988" TOTAL_1="44" TOTAL_2="54" VAR="0.051827801827801834" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.21244282050775537" CI_END="162.29020728628376" CI_START="-76.3853852438469" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="42.95241102121844" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.6448594608993523" P_Q="1.0" P_Z="0.4805389469686633" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="54" TOTAL_2="64" UNITS="" WEIGHT="99.99999999999999" Z="0.7054360084190159">
<NAME>Birthweight</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="179.5436899045189" CI_START="-145.5436899045189" EFFECT_SIZE="17.0" ESTIMABLE="YES" MEAN_1="2903.0" MEAN_2="2886.0" ORDER="2" SD_1="407.0" SD_2="410.0" SE="82.93197792747357" STUDY_ID="STD-Cabero-1988" TOTAL_1="44" TOTAL_2="54" WEIGHT="53.903355202098815"/>
<CONT_DATA CI_END="249.06943463197564" CI_START="-102.46943463197528" EFFECT_SIZE="73.30000000000018" ESTIMABLE="YES" MEAN_1="2471.9" MEAN_2="2398.6" ORDER="3" SD_1="216.9" SD_2="182.7" SE="89.67993086527218" STUDY_ID="STD-Mori-1990" TOTAL_1="10" TOTAL_2="10" WEIGHT="46.09664479790117"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9305967786267486" CI_START="0.700210143428793" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1626794258373205" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.28569157719553895" LOG_CI_START="-0.1547716022210226" LOG_EFFECT_SIZE="0.06545998748725818" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.5601861698681236" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="54" WEIGHT="100.0" Z="0.5825650083778355">
<NAME>Induction of labour</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="1.9305967786267486" CI_START="0.700210143428793" EFFECT_SIZE="1.1626794258373205" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.28569157719553895" LOG_CI_START="-0.1547716022210226" LOG_EFFECT_SIZE="0.06545998748725818" ORDER="4" O_E="0.0" SE="0.25873025191719023" STUDY_ID="STD-Cabero-1988" TOTAL_1="44" TOTAL_2="54" VAR="0.06694134325713272" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.591428067370958" CI_START="0.4592381550592123" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.41353915823538584" LOG_CI_START="-0.33796203645658635" LOG_EFFECT_SIZE="0.037788560889399754" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.8437414204346224" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="54" WEIGHT="100.0" Z="0.19711004824464737">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="2.591428067370958" CI_START="0.45923815505921234" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.41353915823538584" LOG_CI_START="-0.3379620364565863" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="5" O_E="0.0" SE="0.4414355217529734" STUDY_ID="STD-Cabero-1988" TOTAL_1="44" TOTAL_2="54" VAR="0.19486531986531985" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2561986043162925" CI_START="0.10791116211552317" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.36818181818181817" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.09905830655088395" LOG_CI_START="-0.9669336304379971" LOG_EFFECT_SIZE="-0.43393766194355654" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.11055556986833107" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="54" WEIGHT="100.0" Z="1.595700979403861">
<NAME>Umbilical artery pH &lt; 7.2</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="1.2561986043162925" CI_START="0.10791116211552317" EFFECT_SIZE="0.36818181818181817" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.09905830655088395" LOG_CI_START="-0.9669336304379971" LOG_EFFECT_SIZE="-0.43393766194355654" ORDER="6" O_E="0.0" SE="0.626168940532459" STUDY_ID="STD-Cabero-1988" TOTAL_1="44" TOTAL_2="54" VAR="0.39208754208754215" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.0895020766502614E-32" CI_END="4.9625952220607" CI_START="0.012040693174838628" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2444444444444444" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="100.00000000000001" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.6957088530747002" LOG_CI_START="-1.9193485103089378" LOG_EFFECT_SIZE="-0.6118198286171187" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.35908613409370993" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="54" WEIGHT="100.0" Z="0.9171078584413465">
<NAME>Perinatal mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="4.9625952220607035" CI_START="0.012040693174838628" EFFECT_SIZE="0.24444444444444444" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6957088530747005" LOG_CI_START="-1.9193485103089378" LOG_EFFECT_SIZE="-0.6118198286171187" ORDER="7" O_E="0.0" SE="1.536097639994268" STUDY_ID="STD-Cabero-1988" TOTAL_1="44" TOTAL_2="54" VAR="2.3595959595959597" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK>
<FEEDBACK_ITEM ID="FBK-01" NO="1">
<TITLE>Chalmers, April 2001</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY>
<P>The review authors conclude that "There is not enough evidence to evaluate the use of betamimetics in promoting fetal growth. Larger studies are needed to investigate possible adverse effects of long-term betamimetic administration." Surely larger studies are needed primarily to see whether there are any beneficial effects?</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY>
<P>We agree, and have changed the text in the abstract accordingly. </P>
<P>[Summary of response from AM Gülmezoglu, July 2001]</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Summary of comments from Iain Chalmers, April 2001.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>